Evotec AG

483 articles with Evotec AG

• Evotec and Venture Capital Consortium Form 'breakpoint Therapeutics GmbH'

  7/8/2019

  Evotec SE announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec's DNA damage response ("DDR") portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers.

• Evotec completes acquisition of Just Biotherapeutics

  7/3/2019

  Evotec SE announced that the strategic transaction to acquire Just Biotherapeutics, signed on 20 May 2019, has been completed.

• Nosopharm and Evotec enter into collaboration to accelerate development of novel antibiotics

  7/3/2019

  Nosopharm and Evotec SE announce their partnership aimed at advancing Nosopharm’s lead candidate, NOSO-502, to the clinical stage, as well as developing a second-generation Odilorhabdin drug candidate.

• Evotec SE Places First Schuldschein (Promissory Note) Worth EUR 250 M

  6/26/2019

  Evotec SE announced that the Company successfully issued a Schuldschein of EUR 250 m on the capital market.

• LineaRx Ships DNA to Support Therapy Development for Neurodegenerative Diseases

  6/26/2019

  Interest in large-scale Linear DNA for nucleic acid-based therapies continues to rise

• Sensyne Health, Evotec, OSI and the University of Oxford create new partnership called LAB10x to accelerate data-driven drug discovery powered by AI

  6/24/2019

  LAB10x aims to accelerate the commercialisation of the next generation of digital therapeutics and data-driven drug discovery from clinical artificial intelligence research and digital health innovations at the University of Oxford

• 

  New Partnership Will Focus on Spinning Out New Drug Companies, Digital Health

  6/24/2019

  The technologies developed by LAB10x will be applied to generate and analyze “anonymized” patient data sets to improve patient outcomes and accelerate medical research and pharmaceutical R&D.

• Resolutions Of The Annual General Meeting 2019 Of Evotec SE

  6/19/2019

  Evotec SE announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting 2019 with very strong supporting majorities.

• 

  Evotec Receives $23.8 Million Grant from Gates Foundation for Tuberculosis Research

  6/11/2019

  “We are honored to join with The Bill & Melinda Gates Foundation to fight tuberculosis, one of the world’s most deadly infectious diseases,” stated Werner Lanthaler, Evotec’s chief executive officer.

• Evotec Receives $23.8 M Grant To Join The Global Fight Against Tuberculosis

  6/10/2019

  Evotec SE announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis ("TB"), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide.

• Evotec and Celgene further expand iPSC collaboration including new cell type

  6/5/2019

  Evotec SE announced that its strategic alliance with Celgene Corporation has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec.

• Evotec SE to acquire Just Biotherapeutics, Inc.

  5/21/2019

  Evotec SE announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. ("Just.Bio") based in Seattle, WA, USA for up to US$ 90 m (approx. EUR 81 m; EUR/$ fx rate of 1.117) including potential performance-based earn-out components expected within the next three years.

• Evotec jump-starts biologics with acquisition of Just Biotherapeutics

  5/20/2019

  Evotec SE announced the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. ("Just.Bio"), for up to $ 90 m including potential performance-based earn-out components expected within the next three years.

• Evotec to Attend Upcoming May-June 2019 Investor Conferences

  5/15/2019

  Evotec SE announced today that its management will be presenting at and attending the following upcoming conferences:

• Evotec Se Reports First Quarter 2019 Results and Provides Corporate Update

  5/14/2019

  Evotec SE reported financial results and corporate updates for the first quarter of 2019.

• Evotec SE To Report First Quarter 2019 Results On 14 May 2019

  5/7/2019

  Evotec SE will report its financial results for the first quarter of 2019 on Tuesday, 14 May 2019.

• Evotec Completes Repayment Of Eur 140 M Acquisition Loan

  4/18/2019

  Eur 140 m bridge loan was drawn to secure evotec's value chain expansion by successful acquisition of aptuit in august 2017

• Evotec And Indivumed Announce Strategic Drug Discovery Collaboration On Precision Medicine For Colorectal Cancer

  4/11/2019

  The collaboration leverages indivumed's true multi-omics cancer database "Indivutype" and evotec's drug discovery platforms to identify new therapeutics for colorectal cancer

• Evotec AG Completes Conversion Into Evotec SE

  4/1/2019

  Evotec SE announced that it has completed its conversion into a company under European law with its registration in the commercial register of the District Court of Hamburg.

• Evotec And The Mark Foundation For Cancer Research Announce Strategic Collaboration In Immuno-oncology

  3/26/2019

  Evotec and the mark foundation form first collaboration together to advance oncology assets based on evotec's new allosteric inhibitor platform "Targetallomod"